Browse by author
Lookup NU author(s): Dr Amir EnshaeiORCiD,
Professor Anthony MoormanORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
IntroductionThe assessment of treatment response by the measurement of minimal residual disease (MRD) at end of induction (EOI) is the most powerful prognostic factor in acute lymphoblastic leukemia (ALL).The integration of MRD monitoring into risk adapted protocols has been used to successfully personalize therapy intensity.1,2However, MRD alone is not sufficient to fully predict outcome. Somatic genetic abnormalities define fundamentally distinct biological subgroups and several are important prognostic and predictive biomarkers. However, dichotomization of continuous variables leads to loss of statistical power. Current risk stratification algorithms apply risk factors independently which may wrongly assume identical associations across biologically heterogeneous subsets.
Author(s): Bartram J, O'connor D, Enshaei A, Moorman A
Publication type: Article
Publication status: Published
Journal: Clinical Lymphoma, Myeloma and Leukemia
Issue: Supplement 1
Print publication date: 01/09/2019
Online publication date: 28/08/2019
Acceptance date: 02/04/2018
ISSN (print): 2152-2650
ISSN (electronic): 2152-2669
Altmetrics provided by Altmetric